Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data.

Aanika Warner(Krankenhaus Bethanien), Melissa Lauren Abel(National Institutes of Health), Katherine Lee-Wisdom(National Institutes of Health), Amy Hankin(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Marijo Bilušić(National Institutes of Health), Esther Mena(National Institutes of Health), Megan Hausler(National Institutes of Health), Monique Williams(National Institutes of Health), Deborah Jolissaint(Walter Reed National Military Medical Center), Fatima Karzai(National Institutes of Health), Liza Lindenberg(National Institutes of Health), Jeanny B. Aragon-Ching(Virginia Cancer Institute), Catherine Handy Marshall(Johns Hopkins University), Helen Moon(Kaiser Permanente Riverside Medical Center), Laura A. Sena(Johns Hopkins University), Gregory T. Chesnut(Walter Reed Army Institute of Research), William D. Figg(National Institutes of Health), Peter L. Choyke(National Institutes of Health), Edwin M. Posadas(Cedars-Sinai Medical Center)
Journal of Clinical Oncology
May 28, 2026
Cited by 0


Related Papers